Login to Your Account



Orexo Shares Fall as J&J Exits Preclinical Metabolic Alliance

By Cormac Sheridan
Staff Writer

Wednesday, February 1, 2012

Shares in Orexo AB fell more than 10 percent Tuesday on news that the Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc., was terminating an alliance to develop drugs targeting pathways involved in arachidonic acid metabolism.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription